TriNetX Uses AI and RWD to Transform Clinical Trials

 TriNetX, guided by its vision of a connected world where data and intelligence improve human health, has announced new results demonstrating how its TriNetX LIVE platform is transforming the way pharmaceutical companies design and execute clinical trials. By uniting clinically rich real-world data with advanced artificial intelligence capabilities, the platform is delivering measurable reductions in costly protocol amendments while significantly improving the efficiency of clinical trial site identification. These results are now shaping the next generation of innovation across the TriNetX LIVE™ platform.

In early 2026, TriNetX plans to introduce new AI-driven capabilities that will allow researchers to query its global federated network using natural language. This advancement removes long-standing technical barriers that have historically limited access to sophisticated real-world data analytics. Currently in beta with select customers, these capabilities are already enabling early feedback and refinement ahead of a broader launch.

The announcement follows a landmark year for TriNetX, marked by strong industry recognition and global expansion. In 2025, the company earned places on The Healthcare Technology Report’s Top 50 Healthcare Technology Companies and Top 25 Healthcare Software Companies lists and was named a Best of Show finalist at SCOPE Europe. During the same period, TriNetX expanded its global network by millions of patients, further strengthening its position as a leading clinical research intelligence platform.

TriNetX’s impact and scale grew substantially throughout 2025. The company’s global federated network now includes more than 280 million patients, supports over 220 healthcare organizations across four continents, and has identified and mapped more than 10,000 clinical trial sites worldwide. Research powered by the platform supported over 1,400 peer-reviewed publications in 2025 alone, doubling the prior year’s output and bringing the cumulative total to more than 2,500 studies across oncology, cardiology, neurology, and ophthalmology.

According to Steve Kundrot, Chief Operating Officer at TriNetX, these milestones represent more than operational growth. He emphasized that every data point connects to real patient outcomes, enabling trials to fill faster, diseases to be detected earlier, and therapies to reach patients months or even years sooner. He added that TriNetX is focused on removing roadblocks between researchers and actionable insights.

As pharmaceutical companies face rising development costs and persistent trial delays caused by protocol amendments, TriNetX’s AI-powered real-world data platform is helping address some of the industry’s most pressing challenges. In 2025, the company helped sponsors reduce protocol amendments by as much as 50 percent, keeping studies on track and minimizing delays. By shifting site identification from a site-first to a patient-first approach, TriNetX enabled sponsors to identify where eligible patients are already receiving care, leading to higher site acceptance rates and faster response times.

The platform is also improving patient recruitment and early disease detection. Machine learning models applied to inflammatory bowel disease showed significant potential to increase enrollment conversion rates for Crohn’s disease trials, while an AI model developed for pancreatic cancer demonstrated the ability to predict disease risk up to 18 months in advance. By identifying dozens of predictive features and enabling customizable risk thresholds, the model supports earlier intervention strategies and more personalized clinical decision-making. The approach is currently being validated across a prospective cohort of six million patients.

Looking ahead, TriNetX will roll out its most ambitious platform enhancements yet in 2026, designed to make advanced clinical research analytics accessible to researchers regardless of technical expertise. A new conversational AI interface will allow scientists to ask complex research questions in plain language and receive sophisticated analyses instantly, powered by TriNetX’s proprietary clinical ontology and live global data network. At the same time, enhanced API capabilities will enable seamless integration with existing enterprise systems, allowing study queries to be submitted using code or natural language and returning real-time feasibility insights directly into established workflows.

Kundrot noted that when researchers can interact with data in plain language and receive immediate, high-quality insights, it fundamentally changes who can participate in clinical research and how quickly new treatments can reach patients. By breaking down technical barriers and embedding intelligence directly into research workflows, TriNetX aims to accelerate the future of clinical development worldwide.

To join our expert panel discussions, reach out to info@intentamplify.com

Recommended News: 

• HCLTech Partners With Carahsoft for Public Sector IT
• TCS Partners With Kalmar to Lead AI-Driven IT Transformation
• eGain Brings Trusted AI Guidance to Webex Agents